Art. -Nr.: HY-112885A

nor-NOHA acetate

(Synonyms: Nω-Hydroxy-nor-L-arginine acetate)

7 Cited Publications

Kundenbewertung

Based on 7 publication(s) in Google Scholar

nor-NOHA acetate is a selective and reversible Arginase inhibitor. nor-NOHA acetate induces Apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA acetate has anti-leukemic activity. nor-NOHA acetate improves liver ischemia-reperfusion injury. nor-NOHA acetate can used in study of tuberculosis, endothelial dysfunction, immunosuppression and metabolism.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.52%
CAS. Nr.: 1140844-63-8
Formel: C₉H₂₀N₄O₇
Molecular Weight:296.28

Speicherung:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

nor-NOHA acetate Chemical Structure

CAS. Nr.: 1140844-63-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (7)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Arginase^[1]

In Vitro

nor-NOHA (0.1-1 mM, 72 h) acetate induces apoptosis in a dose-dependent manner under hypoxia (1.5% O₂) in K562 cells^[1].
nor-NOHA (1 mM, 72 h) acetate attenuates hypoxia-mediated resistance towards Imatinib (HY-15463) in K562 or KCL22 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Nor-NOHA (0.04 mg/g of mouse; i.p.; daily) acetate modulates arginase to alter immune responses in experimental mouse models of pulmonary tuberculosis, including in the setting of HIV co-infection^[4].
nor-NOHA (100 mg/kg, i.v., once time) acetate induces a significant reduction of infarct size in male Sprague-Dawley rats^[2].
nor-NOHA (100 mg/kg, i.v., once time) acetate increases plasma citrulline and nitrite levels and decreases the ornithine plasma levels in male Sprague-Dawley rats^[2].
nor-NOHA (100 mg/kg; intravenous penile vein injection) acetate improves liver I/R injury^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Sprague-Dawley rats subjected to ischemia-reperfusion^[2]
Dosage:

100 mg/kg
Administration:

Intravenous injection (i.v.)
Result:

Induced a significant reduction of infarct size to 39%.
Did not reduce infarct size when administered together with cPTIO or L-NMMA.

Chemical Information

CAS. Nr. 1140844-63-8
Appearance Solid
Molecular Weight 296.28
Formel C₉H₂₀N₄O₇
Color White to off-white
SMILES

O=C(O)[C@@H](N)CCNC(NO)=N.CC(O)=O.CC(O)=O
Synonyms

Nω-Hydroxy-nor-L-arginine acetate
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (7)

All Bio/Physico-chemical AssayCell Proliferation/Viability AssayFlow CytometryRT-PCR

Sort by:

Journal Impact Factor

Cell

Systemic immune activity occurs during human immune system maturation. [Abstract]

2025 Dec 11;188(25):7291-7308.e23. PMID: 41161316

nor-NOHA acetate purchased from MedChemExpress. Usage Cited in: Cell. 2025 Dec 11;188(25):7291-7308.e23. [Abstract]

Bar plots showing proportions of TNF-α⁺ T cells in fetal liver whole blood following PMA simulation. T cells were cultured alone (light green) or co-cultured with matched fetal neutrophils (orange) in the presence or absence of ARG1 inhibitor (nonor-NOHA monoacetate; overnight) or L-arginine supplementation, as indicated on the x axis.
Free Radic Biol Med

Endothelial Arg2 regulates HIMM-induced mitochondrial hyperfission via affecting arginine metabolism. [Abstract]

2026 Apr:247:516-527. PMID: 41720362
Chin Med

Licoisoflavone A potentiates oxaliplatin efficacy in colorectal cancer by dual targeting arginine metabolism of tumor microenvironment and cancer cells. [Abstract]

2026 May 28;21(1):151. PMID: 42210399
Front Cell Dev Biol

mTOR Signaling Regulates the Development and Therapeutic Efficacy of PMN-MDSCs in Acute GVHD. [Abstract]

2021 Dec 23;9:741911. PMID: 35004668

nor-NOHA acetate purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2021 Dec 23;9:741911. [Abstract]

nor-NOHA monoacetate (nor-NOHA) efficiently reduced immunosuppressive activity. Arg1 inhibitor (nor-NOHA) and/or iNOS inhibitor [L-NG-Monomethylarginine, Acetate Salt (L-NMMA)] were added in PMN-MDSCs’ suppressive function assays.
FASEB J

Spatial Metabolism of Primary Limited Cutaneous Amyloidosis Based on Mass Spectrometry Imaging. [Abstract]

2025 Sep 30;39(18):e71057. PMID: 40955599

nor-NOHA acetate purchased from MedChemExpress. Usage Cited in: FASEB J. 2025 Sep 30;39(18):e71057. [Abstract]

nonor-NOHA monoacetate (1, 10, 50, 100 μM) increased HaCaT cell viability.

nor-NOHA acetate purchased from MedChemExpress. Usage Cited in: FASEB J. 2025 Sep 30;39(18):e71057. [Abstract]

nonor-NOHA monoacetate (100 μM) increased K5 expression in HaCaT cells.
Clin Immunol

MAPK signaling pathway induced LOX-1+ polymorphonuclear myeloid-derived suppressor cells in biliary atresia. [Abstract]

2024 Sep 3:110355. PMID: 39237078
Res Sq

Protective coinfection: influenza reprograms myeloid cells to limit CD8 T cell-mediated malaria pathology. [Abstract]

2026 May 8:rs.3.rs-9404453. PMID: 42147182

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 100 mg/mL (337.52 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3752 mL

16.8759 mL

33.7519 mL

5 mM

0.6750 mL

3.3752 mL

6.7504 mL

10 mM

0.3375 mL

1.6876 mL

3.3752 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (292 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Ng KP, et al. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One. 2018 Oct 11;13(10):e0205254. [Content Brief]

[2]. Jung C, et al. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 2010 Jan 1;85(1):147-54. [Content Brief]

[3]. Reid KM, et al. Liver I/R injury is improved by the arginase inhibitor, N(omega)-hydroxy-nor-L-arginine (nor-NOHA). Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G512-7. [Content Brief]

[4]. Chauhan , et al. Therapeutic Modulation of Arginase with nor-NOHA Alters Immune Responses in Experimental Mouse Models of Pulmonary Tuberculosis including in the Setting of Human Immunodeficiency Virus (HIV) Co-Infection. Trop Med Infect Dis. 2024 Jun 6;9(6):129. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	3.3752 mL	16.8759 mL	33.7519 mL	84.3796 mL
	5 mM	0.6750 mL	3.3752 mL	6.7504 mL	16.8759 mL
	10 mM	0.3375 mL	1.6876 mL	3.3752 mL	8.4380 mL
	15 mM	0.2250 mL	1.1251 mL	2.2501 mL	5.6253 mL
	20 mM	0.1688 mL	0.8438 mL	1.6876 mL	4.2190 mL
	25 mM	0.1350 mL	0.6750 mL	1.3501 mL	3.3752 mL
	30 mM	0.1125 mL	0.5625 mL	1.1251 mL	2.8127 mL
	40 mM	0.0844 mL	0.4219 mL	0.8438 mL	2.1095 mL
	50 mM	0.0675 mL	0.3375 mL	0.6750 mL	1.6876 mL
	60 mM	0.0563 mL	0.2813 mL	0.5625 mL	1.4063 mL
	80 mM	0.0422 mL	0.2109 mL	0.4219 mL	1.0547 mL
	100 mM	0.0338 mL	0.1688 mL	0.3375 mL	0.8438 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

nor-NOHA acetate

7 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

nor-NOHA acetate

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-Cancer Metabolism Compound Library

Anti-tuberculosis Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Amino Acid Metabolism Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) nor-NOHA acetate

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

nor-NOHA acetate

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-Cancer Metabolism Compound Library

Anti-tuberculosis Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Amino Acid Metabolism Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) nor-NOHA acetate

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

nor-NOHA acetate Related Classifications

HY-112885A Related Classifications